Regenerative Medical Solutions
Regenerative Medical Solutions is a Madison, Wisconsin-based preclinical biotech developing iPSC-derived islet-like cluster therapies for Type 1 and Type 2 diabetes, and selling ILC Cell Kits, ProgenMix media, and biotech consulting services to pharma, biotech, and academic researchers globally.
- Company typePrivate
- Founded2012
- HeadquartersMadison, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Regenerative Medical Solutions does
Regenerative Medical Solutions (RMS) is a privately held biotechnology company founded in 2012 in Madison, Wisconsin, developing a prospective functional cure for diabetes based on induced pluripotent stem cell (iPSC) technology. The company's scientific platform, derived from more than 20 years of research in Dr. Jon Odorico's laboratory at the University of Wisconsin-Madison, differentiates human iPSCs into Islet-Like Clusters (ILCs) containing insulin-producing beta cells, alpha cells, and delta cells that morphologically and functionally resemble human cadaveric islets. Its lead therapeutic program is in preclinical development with the goal of restoring natural insulin production in Type 1 and Type 2 diabetes patients without immunosuppression, organ donation, or implantable devices. RMS holds multiple issued US patents and exclusively licenses additional UW-Madison and Yamanaka iPSC patents.
RMS operates a dual revenue model: a commercial research-products business and a therapeutic development pipeline. Commercial offerings include the ILC Cell Kit (cryopreserved single-cell ILCs expressing NKX6.1 and PDX1 markers with demonstrated glucose-stimulated insulin secretion), ProgenMix™ Media Formulation (a chemically defined differentiation protocol achieving >95% PDX1+ pancreatic progenitor purity), and customized biotech consulting services. Products are sold directly to pharmaceutical and biotech companies, academic researchers, and government laboratories, with global distribution enabled through a strategic partnership with MilliporeSigma covering the United States, Europe, and Asia. Therapeutic development is supported by NIH non-dilutive funding, including a $1.8 million Phase II SBIR grant awarded in October 2025, and by private capital raised under an SEC Rule 506(b) exempt offering of up to $5 million. The company employs 1–10 people and is led by Anthony D. Kolton (President and CEO) and Dr. Jon S. Odorico (Scientific Founder), with Dr. Dena E. Cohen as Chief Scientific Officer.
Regenerative Medical Solutions firmographics
Firmographics- Name
- Regenerative Medical Solutions
- Legal name
- Regenerative Medical Solutions, Inc.
- Website
- https://regenmedsolutions.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Regenerative Medical Solutions is a Madison, Wisconsin-based preclinical biotech developing iPSC-derived islet-like cluster therapies for Type 1 and Type 2 diabetes, and selling ILC Cell Kits, ProgenMix media, and biotech consulting services to pharma, biotech, and academic researchers globally.
- Ownership category
- akta.pro rank
Regenerative Medical Solutions industry classification
Industry- Product category
- Regenerative Medicine Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO), Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where Regenerative Medical Solutions is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Regenerative Medical Solutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- NIH Research Grants: RMS receives NIH grant funding to support stem cell-based diabetes therapy development. The company secured a $1.8 million NIH Phase II SBIR grant for proof-of-concept studies including humanized mouse model testing.
- Research Products (ILC Cell Kit, ProgenMix): Sale of stem cell research products including ILC Cell Kit (ready-to-use cryopreserved islet-like clusters) and ProgenMix media formulation to pharmaceutical companies, biotech firms, and academic researchers for drug discovery and toxicity testing.
- Biotech Consulting Services: Customized life science and biotech consulting services offered to pharmaceutical firms, biotech companies, academic researchers, and investment firms seeking expertise in stem cell research and diabetes treatment development.
- Securities Offering: RMS filed a $5 million exempt offering of securities under Rule 506(b) with a minimum investment of $25,000, seeking investment capital for company operations and research development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Minimum investment of $25,000 for exempt securities offering |
| Other | Multi-year contract | Custom consulting engagement pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Regenerative Medical Solutions product offering
Product offeringCore offering
Regenerative Medical Solutions is a biotechnology company developing an iPSC-derived Islet-Like Cluster (ILC) cellular therapy for Type 1 and Type 2 diabetes currently in pre-clinical development. The company also sells research-use products (ILC Cell Kit and ProgenMix media formulation) to pharmaceutical and academic customers for drug discovery and toxicity testing, and provides customized biotech consulting services in stem cell and diabetes research.
Product overview
Regenerative Medical Solutions (RMS) operates as a biotechnology company with a dual-focus product portfolio: a core therapeutic development program and commercial research products. The therapeutic program centers on an iPSC-derived Islet-Like Cluster (ILC) cellular therapy for diabetes currently in pre-clinical development. Complementing this, RMS offers two research products—the ILC Cell Kit (ready-to-use cryopreserved islet-like cells) and ProgenMix™ Media Formulation (a differentiation protocol for generating pancreatic progenitor cells)—both serving pharmaceutical companies, biotech firms, and academic researchers for drug discovery and toxicity screening. Additionally, RMS provides biotech consulting services leveraging its stem cell and diabetes research expertise. The company was founded in 2012 based on research from Dr. Jon Odorico's laboratory at the University of Wisconsin–Madison.
Differentiator
Problem solved
Functional benefit
Brands
- ILC Cell Kit: A specialized stem cell research product containing cryopreserved single-cell islet-like clusters (ILCs) for diabetes research, drug discovery, and toxicity testing.
- ProgenMix™
Products and services
- Stem Cell Therapy for Diabetes iPSC-derived Islet-Like Cluster (ILC) cellular therapy in pre-clinical development for treating Type 1 and Type 2 diabetes. The therapy aims to restore natural insulin production without requiring immunosuppression or organ donation, utilizing both autologous and allogeneic approaches.
- ILC Cell Kit Cryopreserved single-cell Islet-Like Clusters (ILCs) derived from human induced pluripotent stem cells (iPSCs) for diabetes research, drug discovery, toxicity testing, and pre-clinical studies. The cells express key pancreatic markers (NKX6.1 and PDX1), demonstrate functional insulin production with glucose-stimulated insulin secretion (GSIS), and are morphologically similar to human cadaveric islets.
- ProgenMix Media Formulation A chemically defined cell culture media formulation and four-stage differentiation protocol for generating PDX1+ pancreatic progenitor cells (greater than 95% purity) and endocrine cell types from human iPSC or embryonic stem cell lines. Enables researchers to produce their own pancreatic cells for drug discovery and toxicity testing applications.
- Biotech Consulting Services Customizable life science and biotech consulting services for stem cell research, iPSC development, diabetes research, preclinical study design, regulatory navigation, pharmaceutical development, and technology commercialization strategy. Offered globally via remote and in-person engagements.
Quantifiable outcome
- Human iPSC-derived ILCs show morphological and functional similarity to human cadaveric islets
- +2 more outcomes
Companies that use Regenerative Medical Solutions
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Regenerative Medical Solutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Regenerative Medical Solutions partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MilliporeSigma (Sigma-Aldrich)coreRMS has established a strategic partnership with MilliporeSigma to expand access to its iPSC-derived cell products through established ecommerce channels and global sales networks. This collaboration enhances RMS's market reach and facilitates integration into existing pharmaceutical and biotechnology procurement systems, enabling international distribution to Europe and Asia.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Regenerative Medical Solutions competitors and assessment
Company assessmentDirect peers
- Vertex Pharmaceuticals: Vertex is developing VX-880, a stem cell-derived islet cell therapy for Type 1 diabetes currently in clinical trials (acquired via Semma Therapeutics). It is the most advanced and best-capitalized direct competitor to RMS in the iPSC-derived beta cell space.
- ViaCyte: ViaCyte (now part of Vertex/Crumpline) developed PEC-Direct and VC-02, stem cell-derived islet therapies for diabetes using encapsulation devices. Directly comparable to RMS in target indication (Type 1 diabetes) and cell therapy modality.
- Semma Therapeutics: Semma was a leading developer of iPSC-derived islet cell therapies for diabetes, acquired by Vertex for $950M in 2019. RMS competes in the same iPSC-to-beta-cell differentiation space and could itself be a similar acquisition target.
- BlueRock Therapeutics: BlueRock Therapeutics (a Bayer subsidiary) is a leading iPSC-derived cell therapy developer with programs in multiple indications. While its lead programs are in cardiology and neurology, its iPSC manufacturing platform and approach are technically comparable to RMS.
Emerging players
- Sigilon Therapeutics: Sigilon developed encapsulated cell therapies, including programs for Type 1 diabetes using stem cell-derived beta cells in immune-shielding spheres. Comparable in cell-therapy modality for diabetes though it pursued an encapsulation rather than immune-evasion approach.
- Seraxis: Seraxis is developing stem cell-derived islet cell therapies for insulin-dependent diabetes, with an emphasis on immune-evasive cell encapsulation. Directly comparable therapeutic focus and pre-clinical/early-clinical stage to RMS.
- Diatranz Otsuka Limited (DOL): Diatranz Otsuka Limited is developing DIABECELL, an encapsulated porcine islet cell therapy for Type 1 diabetes. Comparable in targeting islet cell replacement for diabetes with an alternative (xenogeneic) cell source.
- Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies (initially in oncology) with a focus on immune evasion through gene editing. Its iPSC differentiation and immune-evasion engineering approaches are technologically comparable to RMS's platform.
- Fate Therapeutics: Fate Therapeutics develops iPSC-derived NK and T-cell immunotherapies with an off-the-shelf, allogeneic approach. Comparable iPSC platform foundation and pursuit of universal-donor cell therapies, though in a different therapeutic area.
Broad incumbents
- Humacyte: Humacyte is a regenerative medicine company developing bioengineered human tissues at scale. It is a broader incumbent in regenerative medicine that, like RMS, pursues manufactured living-cell therapeutics requiring complex GMP scale-up, providing a comparable commercial-readiness trajectory.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Regenerative Medical Solutions social profiles
Digital presenceRegenerative Medical Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regenerative Medical Solutions leadership team
Management profileNumber of profiles
Profiles5 records
Regenerative Medical Solutions funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regenerative Medical Solutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regenerative Medical Solutions
What does Regenerative Medical Solutions do?
Regenerative Medical Solutions is a biotechnology company developing an iPSC-derived Islet-Like Cluster (ILC) cellular therapy for Type 1 and Type 2 diabetes currently in pre-clinical development. The company also sells research-use products (ILC Cell Kit and ProgenMix media formulation) to pharmaceutical and academic customers for drug discovery and toxicity testing, and provides customized biotech consulting services in stem cell and diabetes research.
Is Regenerative Medical Solutions a public or private company?
Regenerative Medical Solutions is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Regenerative Medical Solutions founded?
Regenerative Medical Solutions was founded in 2012. It employs 1 to 10 people.
Where is Regenerative Medical Solutions based?
Regenerative Medical Solutions is headquartered in Madison, United States, in the North America region.
How does Regenerative Medical Solutions make money?
Four revenue lines are on record. NIH Research Grants are the primary driver. The others are research Products (ILC Cell Kit, ProgenMix), biotech Consulting Services and securities Offering.
Who are Regenerative Medical Solutions's main competitors?
Direct peers on record are Vertex Pharmaceuticals, ViaCyte, Semma Therapeutics and BlueRock Therapeutics. Emerging players are Sigilon Therapeutics, Seraxis, Diatranz Otsuka Limited (DOL), Century Therapeutics and Fate Therapeutics. Humacyte is listed as a broad incumbent.
Does Regenerative Medical Solutions have an API?
No public API is recorded for Regenerative Medical Solutions.
What industry is Regenerative Medical Solutions in?
Regenerative Medical Solutions's product category is Regenerative Medicine Therapeutics. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2836.